DESTINA GENOMICA SLNE

Their core work

Destina Genomica is a Spanish biotech SME based in Granada that develops diagnostic technologies based on peptide nucleic acids (PNA) and biosensor platforms. Their core work centers on molecular diagnostics — detecting microRNAs and circulating cell-free RNA in biological fluids for cancer screening and infectious disease identification. They build sensor-based tools for liquid biopsy applications, targeting conditions from colorectal and prostate cancer to drug-resistant tuberculosis. Their technology enables detection of disease biomarkers without invasive tissue sampling.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2018), Destina Genomica contributed as a partner or third party to projects focused on biosensor development and biophotonic detection methods (miRNA-DisEASY, Liqbiopsens, Halo), building foundational capabilities in microRNA detection without yet leading their own projects. From 2019 onward, they sharpened their focus significantly — first applying their molecular diagnostics expertise to tuberculosis (ARREST-TB), then stepping up as coordinator of diaRNAgnosis, their own platform for direct RNA profiling using PNA and microsphere technologies. The trajectory shows a company that matured from contributing specialist know-how to others' projects into leading its own diagnostic platform development.

Destina Genomica is moving toward owning its diagnostic platform — their coordination of diaRNAgnosis (running until 2025) signals a shift from component supplier to platform developer in liquid biopsy diagnostics.

How they like to work

Destina Genomica has primarily operated as a specialist contributor — joining consortia in 3 projects and once as a third party — before stepping into a coordinator role with diaRNAgnosis. With 29 unique partners across 13 countries from just 5 projects, they work in moderately sized international consortia rather than small bilateral arrangements. Their shift to coordination in their most recent project suggests a company gaining confidence and visibility in its field, making them a more assertive partner going forward.

Destina Genomica has built a broad European network of 29 partners across 13 countries through 5 projects — a wide reach for an SME of this size, indicating they are well-connected within the molecular diagnostics and biosensor research communities.

What sets them apart

Destina Genomica occupies a niche at the intersection of peptide nucleic acid chemistry and biosensor engineering — a combination that few SMEs offer for point-of-care molecular diagnostics. Their ability to apply the same core PNA technology across both cancer liquid biopsy and infectious disease detection (TB) demonstrates genuine platform versatility, not just single-application capability. For consortium builders, they bring a rare profile: a small company with proprietary chemistry that has proven it can both contribute specialist components and coordinate its own EU projects.

Highlights from their portfolio

• diaRNAgnosis
  Their first coordinator role — signals company maturity and ownership of a direct RNA profiling platform for cancer biomarker detection in biofluids.
• ARREST-TB
  Largest single EC grant (EUR 417,911) and a strategic pivot applying their molecular diagnostics expertise to tuberculosis, demonstrating cross-disease versatility.
• Liqbiopsens
  Early involvement (as third party) in liquid biopsy for colorectal cancer — established their credentials in this now-booming diagnostic field.